CRP and heart failure: In the CANTOS trial [123] of 10061 prior myocardial infarction patients with a high-sensitivity CRP level ≥ 2 mg/L, canakinumab (a monoclonal antibody targeting IL-1ß) therapy reduced recurrent cardiovascular events (HR 0.85, p = 0.021) over median 3.7 years follow-up, and there was a dose-dependent reduction in heart failure hospitalisation and heart failure-related mortality (p = 0.037) [124], although MVO specifically was not evaluated.